This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Small-Cap Winners & Losers

Cytomedix (GTF) was one of the biggest winners, both among small-cap stocks and overall, amid a mostly bullish session Friday.

Shares of the Rockville, Md., biotech company skyrocketed some 125% after the Food and Drug Administration approved its wound-closing AutoloGel System for use on various sorts of ulcers, as well as for the management of mechanically or surgically debrided wounds. Shares soared $1.47 to $2.64.

HandHeld Entertainment (ZVUE) also rode high after the maker of Zvue portable media players announced that comScore Media Matrix has named it the "fastest growing Web property" for August, citing a 327% surge in unique U.S. visitors to its Web-based network vs. July. Shares of the San Francisco-based company vaulted more than 65% to $2.90.

Elsewhere, Cowen & Co. started coverage on Savient Pharmaceuticals (SVNT) with an outperform rating, saying its proposed gout treatment Puricase -- meant for patients who haven't responded to other treatments -- is promising and has significant revenue potential. Shares leapt 81 cents, or 6.1%, to $14.06.

The Russell 2000 and the S&P SmallCap 600 added 0.4% and 0.1%, respectively, boosted by gains at both Savient and at Genesco (GCO - Get Report), which filed a lawsuit seeking to force Finish Line (FINL - Get Report) to close the $1.5 billion merger the footwear retailers inked in June.

Earlier this month, UBS -- which is slated to fund the takeout -- told Finish Line that it was " extremely concerned " about Genesco's financial health and might withhold financing if Genesco has undergone a "Material Adverse Effect" as defined in the related agreement.

Shares of Nashville, Tenn.-based Genesco were up 1.5% to $47.46; Finish Line, based in Indianapolis, slipped 0.6% at $5.26.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZVUE $0.00 0.00%
SVNT $0.00 0.00%
FINL $20.45 2.35%
GCO $67.87 -0.35%
PRFT $20.31 -2.73%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs